These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25054660)

  • 1. Magnetic resonance spectroscopic imaging in the era of pseudoprogression and pseudoresponse in glioblastoma patient management.
    Shim H; Holder CA; Olson JJ
    CNS Oncol; 2013 Sep; 2(5):393-6. PubMed ID: 25054660
    [No Abstract]   [Full Text] [Related]  

  • 2. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
    Strauss SB; Meng A; Ebani EJ; Chiang GC
    Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [MR imaging for accurate response monitoring in glioblastoma multiforme during bevacizumab therapy].
    Korn A; Braun C; Fenchel M; Ernemann U; Horger M
    Rofo; 2012 May; 184(5):397-401. PubMed ID: 22576602
    [No Abstract]   [Full Text] [Related]  

  • 4. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
    Strauss SB; Meng A; Ebani EJ; Chiang GC
    Neuroimaging Clin N Am; 2021 Feb; 31(1):103-120. PubMed ID: 33220823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
    Payer F
    Wien Med Wochenschr; 2011 Jan; 161(1-2):13-9. PubMed ID: 21312094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convection-enhanced drug delivery: prospects for glioblastoma treatment.
    Barua NU; Gill SS
    CNS Oncol; 2014; 3(5):313-6. PubMed ID: 25363001
    [No Abstract]   [Full Text] [Related]  

  • 7. Imaging of the Posttherapeutic Brain.
    Telles BA; D'Amore F; Lerner A; Law M; Shiroishi MS
    Top Magn Reson Imaging; 2015 Jun; 24(3):147-54. PubMed ID: 26049818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioblastoma: clinical presentation, diagnosis, and management.
    McKinnon C; Nandhabalan M; Murray SA; Plaha P
    BMJ; 2021 Jul; 374():n1560. PubMed ID: 34261630
    [No Abstract]   [Full Text] [Related]  

  • 9. The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
    Bulik M; Kazda T; Slampa P; Jancalek R
    Biomed Res Int; 2015; 2015():641023. PubMed ID: 26448943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma.
    Seidel C; Dörner N; Osswald M; Wick A; Platten M; Bendszus M; Wick W
    BMC Cancer; 2011 Apr; 11():127. PubMed ID: 21481277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images.
    De Edelenyi FS; Rubin C; Estève F; Grand S; Décorps M; Lefournier V; Le Bas JF; Rémy C
    Nat Med; 2000 Nov; 6(11):1287-9. PubMed ID: 11062544
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuroimaging and genetic influence in treating brain neoplasms.
    Hygino da Cruz LC; Kimura M
    Neuroimaging Clin N Am; 2015 Feb; 25(1):121-40. PubMed ID: 25476517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton MR spectroscopic imaging of human glioblastomas at 1.5 Tesla.
    Hnilicová P; Richterová R; Kantorová E; Bittšanský M; Baranovičová E; Dobrota D
    Gen Physiol Biophys; 2017 Dec; 36(5):531-537. PubMed ID: 29372686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
    Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
    Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
    Stuplich M; Hadizadeh DR; Kuchelmeister K; Scorzin J; Filss C; Langen KJ; Schäfer N; Mack F; Schüller H; Simon M; Glas M; Pietsch T; Urbach H; Herrlinger U
    J Clin Oncol; 2012 Jul; 30(21):e180-3. PubMed ID: 22689800
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Reasoning: Worsening neurologic symptoms in a brain tumor patient.
    Faivre G; Pentsova E; Demopoulos A; Taillibert S; Rosenblum M; Omuro A
    Neurology; 2015 Aug; 85(7):e57-61. PubMed ID: 26283762
    [No Abstract]   [Full Text] [Related]  

  • 18. Lesional reflex epilepsy associated with the thought of food.
    El Bouzidi K; Duncan S; Whittle IR; Butler CR
    Neurology; 2010 Feb; 74(7):610-2. PubMed ID: 20157165
    [No Abstract]   [Full Text] [Related]  

  • 19. Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients.
    Cordova JS; Shu HK; Liang Z; Gurbani SS; Cooper LA; Holder CA; Olson JJ; Kairdolf B; Schreibmann E; Neill SG; Hadjipanayis CG; Shim H
    Neuro Oncol; 2016 Aug; 18(8):1180-9. PubMed ID: 26984746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas.
    Beppu T; Inoue T; Shibata Y; Yamada N; Kurose A; Ogasawara K; Ogawa A; Kabasawa H
    Surg Neurol; 2005 Jan; 63(1):56-61; discussion 61. PubMed ID: 15639528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.